Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Target Price from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned an average recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $32.60.

Several analysts have recently commented on SLN shares. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Tuesday, September 16th. Wall Street Zen upgraded shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Wednesday, October 8th.

Silence Therapeutics Trading Up 1.0%

Silence Therapeutics stock opened at $6.20 on Wednesday. The stock has a 50 day moving average of $6.64 and a two-hundred day moving average of $5.93. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $8.08. The stock has a market capitalization of $292.83 million, a price-to-earnings ratio of -4.59 and a beta of 1.35.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Silence Therapeutics had a negative return on equity of 61.76% and a negative net margin of 254.25%.The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $3.28 million. Equities analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SLN. GAMMA Investing LLC boosted its position in shares of Silence Therapeutics by 134.1% during the 2nd quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock worth $48,000 after purchasing an additional 4,773 shares in the last quarter. EHP Funds Inc. purchased a new stake in Silence Therapeutics during the third quarter worth about $55,000. Beacon Pointe Advisors LLC purchased a new stake in Silence Therapeutics during the second quarter worth about $67,000. Jump Financial LLC acquired a new position in Silence Therapeutics during the first quarter worth about $74,000. Finally, Evelyn Partners Investment Management Services Ltd increased its holdings in Silence Therapeutics by 481.3% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after buying an additional 11,868 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.